肺表面活性物质治疗新生儿呼吸窘迫综合征的临床价值分析

Clinical value analysis of lung surface active substance treating neonatal respiratory distress syndrome

目的探讨肺表面活性物质(PS)治疗新生儿呼吸窘迫综合征(NRDS)的临床疗效。方法将本院128例患有NRDS的新生儿依据用药方案差异分为两组,其中63例给予吸痰、吸氧、机械通气等常规治疗设为对照组,其余65例在此前提下采用PS制剂气管内给药设为观察组,对比两组疗效。结果两组治疗6 h后PaO2、pH、PaO2/FiO2值均显上升趋势(P<0.05),而PCaO2下降显著(P<0.05);两组并发症分别为23.08%与41.27%,观察组相对较低(P<0.05);两组住院与机械通气时间及其疗效(分别为95.38%与82.54%)对比观察组均更为理想,组间差异具有统计学意义(P<0.05)。结论将PS用于对新生儿NRDS的治疗,可明显改善其临床病症与缩短治疗时间,也有利于降低其并发症发生率和提高疗效,该法深具临床推广价值。

Objective To study clinical value of lung surface active substance treating neonatal respiratory distress syndrome. Methods Choosing 128 newborns with NRDS in our hospital and dividing them into two groups according to drug difference, of which 63 cases were given conventional treatment, such as sputum aspiration, oxygen, mechanical ventilation, as control group, the remaining 65 cases under the premise on PS preparation endotracheal medication as observation group. Curative effect of two groups were compared. Results PaO2, pH value, PaO2/FiO2 in the two groups after treatment 6 hours showed rising trend （P〈0.05）, while PCaO2 decreased significantly （P〈0.05）;complications in the two groups were 23.08%and 41.27%, relatively low in observation group （P〈0.05）;in the two groups in the hospital with mechanical ventilation time and its curative effect （95.38%, 82.54%respectively） compared to observation group were more ideal, with obviously difference between groups （P〈0.05）. Conclusion Applying PS to the treatment of neonatal NRDS, can obviously improve the clinical symptoms and shorten the treatment time, and also can reduce the incidence of complications and improve curative effect, so it is worthy of clinical promotion.